The invention relates to a pharmaceutical composition comprising the combination of (i) at least one biocompatible nanoparticle, said biocompatible nanoparticle comprising at least one oligomer of albumin (n2) or consisting in an oligomer of albumin, and of (ii) at least one compound of interest, typically at least one pharmaceutical compound, to be administered to a subject in need of such at least one compound of interest, wherein the at least one nanoparticle potentiates the at least one compound of interest efficiency. The longest dimension of the biocompatible nanoparticle is typically between about 4 and about 500 nm. The invention also relates to such a composition for use for administering the at least one compound of interest in a subject in need thereof, wherein the at least one biocompatible nanoparticle and the at least one compound of interest are to be administered in said subject sequentially, typically between more than 5 minutes and about 72 hours one from each other.本發明係關於一種包括以下之組合之醫藥組合物：(i)至少一種生物相容奈米粒子，該生物相容奈米粒子包括至少一種白蛋白寡聚物(n2)或存在有白蛋白寡聚物，及(ii)至少一種所關注化合物，通常係至少一種欲投與需要該至少一種所關注化合物之個體之醫藥化合物，其中該至少一種奈米粒子加強該至少一種所關注化合物之效率。該生物相容奈米粒子之最長尺寸通常介於約4nm與約500nm之間。本發明亦係關於用於將該至少一種所關注化合物投與需要其之個體之此組合物，其中該至少一種生物相容奈米粒子及該至少一種所關注化合物通常係依彼此間隔介於超過5分鐘與約72小時之間，依序投與該個體。
